


WHAT IS CLAIMED IS:

1. A compound having the structural formula I:




FORMULA I

5

or a pharmaceutically acceptable salt thereof, wherein,

X is O or S;

Y¹ is

- 1) CH₂CH₂,
 2) CHCH, or
 3)  ;

10



Y is C(O) or CH(OH);

A and W are independently selected from the group consisting of

- 1) a bond, and
 2) C 1-6 alkylene, unsubstituted or substituted with 1, 2, 3, or 4 halogen atoms;

15


Z is

- 1) O,
 2) S,
 3) 
 4) CH₂
 5) HC=CH,
 6) C≡C, or
 7) a disubstituted aryl or heteroaryl ring, wherein one ring atom of the ring is attached to the moiety -W-R¹

20

25

and another ring atom is attached to the moiety



with the proviso that when Z is O or S, then A and W are independently selected from the group consisting of C₁₋₆ alkylene, unsubstituted or substituted with 1, 2,

5 3, or 4 halogen atoms;

R¹ is

COR⁵,

OH,

CN,

10 (CH₂)₁₋₃ CO₂R⁶,

(CH₂)₀₋₄ SO₃R⁶,

CF₂SO₂NH₂,

SO₂NH₂,

SO₂NHCOR⁸,

15 PO(OH)₂,

C₁₋₄ alkoxy,

hydroxymethylketone,

(CH₂)₀₋₄ heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with 1

to 3 groups of R^a, or

20 tetrazole;

R² is

1) C₁₋₆alkyl, provided that R² is not n-pentyl,

2) (CH₂)₀₋₈C₆₋₁₀aryl,

3) (CH₂)₀₋₈C₅₋₁₀heteroaryl,

25 4) (CH₂)₀₋₈C₃₋₁₀heterocycloalkyl,

5) (CH₂)₀₋₈C₃₋₈cycloalkyl,

6) O-C₁₋₁₀alkyl,

7) O-C₆₋₁₀aryl,

8) O-C₅₋₁₀heteroaryl,

30 9) O-C₅₋₁₀heterocycloalkyl,

10) O-C₃₋₁₀cycloalkyl

wherein aryl, heteroaryl, heterocycloalkyl, and cycloalkyl are unsubstituted or substituted with 1-3 groups of R^b;

R³ and R⁴ are independently selected from the group consisting of

- 5 1) hydrogen,
 2) halogen, and
 3) C₁₋₆ alkyl, or

R³ and R⁴, together with the carbon atom to which they are attached, form a C₃₋₇ cycloalkyl ring;

10 R⁵ is

- 1) hydrogen,
 2) OH,
 3) CH₂OH,
 4) C₁₋₆ alkoxy,
15 5) NHPO₂R⁶,
 6) NHR⁹,
 7) NHSO₂R⁸, or
 8) NR⁶R⁷;

R⁶ and R⁷ are independently selected from the group consisting of hydrogen and

20 C₁₋₆ alkyl;

R⁸ is selected from the group consisting of hydrogen, C₆₋₁₀aryl, and C₁₋₄alkyl;

R⁹ is acyl or sulfonyl; and

R^a and R^b are independently selected from the group consisting of

- 1) C₁₋₆alkoxy,
25 2) C₁₋₆alkyl, unsubstituted or substituted with
 a) C₁₋₆ alkoxy,
 b) C₁₋₆ alkylthio,
 c) CN,
 d) OH, or
30 e) CF₃,
 3) CF₃,
 4) nitro,
 5) amino,
 6) cyano,

- 7) C₁₋₆alkylamino,
8) halogen
9) OR^c,
10) OCH₂R^c, and
5 11) CH₂OR^c;
R^c is
1) C₆₋₁₀aryl,
2) C₅₋₁₀heteroaryl,
3) C₃₋₁₀heterocycloalkyl, or
10 4) C₃₋₈cycloalkyl.


2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is
1) cyclohexyl,
15 2) unsubstituted aryl, or
3) aryl substituted with
a) unsubstituted C₁₋₆ alkyl,
b) C₁₋₆ alkyl substituted with C₁₋₆ alkoxy
c) halogen, or
20 d) CF₃.

3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein R¹ is tetrazole or COR⁵, wherein R⁵ is CH₂OH or OH.

- 25 4. A compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein A is a bond, (CH₂)₁₋₄, or (CH₂)₁₋₅CF₂, and W is a bond or (CH₂)₁₋₆.

5. A compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein Z is
30 1) CH₂,
2) CH=CH,
3) C≡C,
4) O,

5) S,



7) disubstituted thiophene,

8) disubstituted furan, or

5 9) disubstituted benzene; and

R³ and R⁴ are independently selected from the group consisting of hydrogen and F, or R³ and R⁴, together with the carbon atom to which they are attached, form a cyclopropyl or cyclohexyl ring.

10

6. A compound of Claim 5 selected from the group consisting of

7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}heptanoic acid,

15 7-{4-[(1*E*)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}heptanoic acid,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

4-[(1*E*)-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

20 4-[(1*E*)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

4-(3-hydroxy-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

4-(4,4-difluoro-3-hydroxy-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

25 7-(4-{(1*E*)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-2-oxo-1,3-thiazolidin-3-yl)heptanoic acid,

4-{(1*E*)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

4-[(1*E*)-4-cyclohexyl-4,4-difluoro-3-hydroxybut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

30 4-[(1*E*)-4-cyclohexyl-3-hydroxybut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,

- 4-(4,4-difluoro-3-oxo-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,
4-(3-oxo-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,
4-[2-(2,2-difluoro-1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,
5 4-[2-(1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,
4-[2-(1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-thiazolidin-2-one,
10 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-(7-hydroxy-6-oxoheptyl)-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(2*E*)-6-(1*H*-tetraazol-5-yl)hex-2-enyl]-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(3*E*)-6-(1*H*-tetraazol-5-yl)hex-3-enyl]-1,3-thiazolidin-2-one,
15 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(4*E*)-6-(1*H*-tetraazol-5-yl)hex-4-enyl]-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(2*Z*)-6-(1*H*-tetraazol-5-yl)hex-2-enyl]-1,3-thiazolidin-2-one,
20 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(3*Z*)-6-(1*H*-tetraazol-5-yl)hex-3-enyl]-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(4*Z*)-6-(1*H*-tetraazol-5-yl)hex-4-enyl]-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-4-ynyl]-1,3-thiazolidin-2-one,
25 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-2-ynyl]-1,3-thiazolidin-2-one,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-3-ynyl]-1,3-thiazolidin-2-one,
30 5-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)thiophene-2-carboxylic acid,
5-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)-2-furoic acid,
4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[5-(1*H*-tetraazol-5-yl)-2-furyl]propyl}-1,3-thiazolidin-2-one,
35

- 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]propyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*E*)-3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]prop-2-enyl}-1,3-thiazolidin-2-one,
 5 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*E*)-3-[5-(1*H*-tetraazol-5-yl)-2-furyl]prop-2-enyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*Z*)-3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]prop-2-enyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*Z*)-3-[5-(1*H*-tetraazol-5-yl)-2-furyl]prop-2-enyl}-1,3-thiazolidin-2-one,
 10 3-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)benzoic acid,
 4-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)benzoic acid,
 15 2-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)benzoic acid,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[3-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[2-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-thiazolidin-2-one,
 20 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[4-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[3-(1*H*-tetraazol-5-yl)methyl]phenyl}ethyl}-1,3-thiazolidin-2-one,
 25 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[4-(1*H*-tetraazol-5-yl)methyl]phenyl}ethyl}-1,3-thiazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[2-(1*H*-tetraazol-5-yl)methyl]phenyl}ethyl}-1,3-thiazolidin-2-one,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}-
 30 2,2-difluoroheptanoic acid,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}-4,4-difluoroheptanoic acid,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}-5,5-difluoroheptanoic acid,

- 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}-6,6-difluoroheptanoic acid,
 4-(2-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}ethoxy)butanoic acid,
 5 3-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propoxy)propanoic acid,
 (4-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}butoxy)acetic acid,
 [(4-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}butyl)thio]acetic acid,
 10 3-[(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}propyl)thio]propanoic acid,
 4-[(2-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-thiazolidin-3-yl}ethyl)thio]butanoic acid,
 15 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}heptanoic acid,
 7-{4-[(1*E*)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}heptanoic acid,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 20 4-[(1*E*)-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-(3-hydroxy-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 25 4-(4,4-difluoro-3-hydroxy-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 7-(4-{(1*E*)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-2-oxo-1,3-oxazolidin-3-yl)heptanoic acid,
 4-{(1*E*)-4,4-difluoro-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 30 4-[(1*E*)-4-cyclohexyl-4,4-difluoro-3-hydroxybut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4-cyclohexyl-3-hydroxybut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,

- 4-(4,4-difluoro-3-oxo-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-(3-oxo-4-phenylbutyl)-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[2-(2,2-difluoro-1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[2-(1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[2-(1-hydroxy-2-phenylethyl)cyclopropyl]-3-[6-(1*H*-tetraazol-5-yl)hexyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-(7-hydroxy-6-oxoheptyl)-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(2*E*)-6-(1*H*-tetraazol-5-yl)hex-2-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(3*E*)-6-(1*H*-tetraazol-5-yl)hex-3-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(4*E*)-6-(1*H*-tetraazol-5-yl)hex-4-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(2*Z*)-6-(1*H*-tetraazol-5-yl)hex-2-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(3*Z*)-6-(1*H*-tetraazol-5-yl)hex-3-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[(4*Z*)-6-(1*H*-tetraazol-5-yl)hex-4-enyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-4-ynyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-2-ynyl]-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(1*H*-tetraazol-5-yl)hex-3-ynyl]-1,3-oxazolidin-2-one,
 5-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)thiophene-2-carboxylic acid,
 5-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)-2-furoic acid,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[5-(1*H*-tetraazol-5-yl)-2-furyl]propyl}-1,3-oxazolidin-2-one,

- 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]propyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*E*)-3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]prop-2-enyl}-1,3-oxazolidin-2-one,
 5 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*E*)-3-[5-(1*H*-tetraazol-5-yl)-2-furyl]prop-2-enyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*Z*)-3-[5-(1*H*-tetraazol-5-yl)thien-2-yl]prop-2-enyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{(2*Z*)-3-[5-(1*H*-tetraazol-5-yl)-2-furyl]prop-2-enyl}-1,3-oxazolidin-2-one,
 10 3-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)benzoic acid,
 4-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)benzoic acid,
 15 2-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)benzoic acid,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[3-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[2-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-oxazolidin-2-one,
 20 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[4-(1*H*-tetraazol-5-yl)phenyl]propyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[3-(1*H*-tetraazol-5-yl)methyl]phenyl]ethyl}-1,3-oxazolidin-2-one,
 25 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[4-(1*H*-tetraazol-5-yl)methyl]phenyl]ethyl}-1,3-oxazolidin-2-one,
 4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{2-[2-(1*H*-tetraazol-5-yl)methyl]phenyl]ethyl}-1,3-oxazolidin-2-one,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}-
 30 2,2-difluoroheptanoic acid,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}-
 4,4-difluoroheptanoic acid,
 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}-
 5,5-difluoroheptanoic acid,

- 7-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}-6,6-difluoroheptanoic acid,
 4-(2-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethoxy)butanoic acid,
 5 3-(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propoxy)propanoic acid,
 (4-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}butoxy)acetic acid,
 [(4-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}butyl)thio]acetic acid,
 10 3-[(3-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}propyl)thio]propanoic acid,
 4-[(2-{4-[(1*E*)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazolidin-3-yl}ethyl)thio]butanoic acid,
 15
 or a pharmaceutically acceptable salt thereof.

7. A method for treating disorders related to elevated intraocular pressure by: treating ocular hypertension, treating glaucoma, treating macular edema,
 20 treating macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve tension, providing a neuroprotective effect or treating dry eyes, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of therapeutically effective amount of a compound of Claim 1.

25

8. A method according to Claim 7 wherein the topical formulation optionally contains xanthan gum or gellan gum.

9. A method according to Claim 8 wherein the topical formulation
 30 is a solution or suspension.

10. A method according to Claim 7 further comprising administering to the patient an active ingredient selected from the group consisting of a β -adrenergic blocking agent, a parasympatho-mimetic agent, a sympathomimetic

agent, a carbonic anhydrase inhibitor, a prostaglandin, a hypotensive lipid, a neuroprotectant, and a 5-HT₂ receptor agonist, is added to the formulation.

11. A method according to Claim 10 wherein the β -adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the
5 parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine; the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescala, or S1033; the hypotensive lipid is lumigan; the neuroprotectant is eliprodil, R-eliprodil or
10 memantinel; and the 5-HT₂ receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.

12. A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A compound of formula I, as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use as a selective agonist of the
15 EP₄ subtype of prostaglandin E₂ receptor.

14. Use of a compound of formula I, as defined in any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a
20 medicament for treating disorders related to elevated intraocular pressure by: treating ocular hypertension, treating glaucoma, treating macular edema, treating macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve tension, providing a neuroprotective effect or treating dry eyes.

15. A formulation according to claim 12 in a form for topical
25 administration, for treating disorders related to elevated intraocular pressure by: treating ocular hypertension, treating glaucoma, treating macular edema, treating macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve tension, providing a neuroprotective effect or treating dry eyes.